Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Page, Elizabeth CBancroft, Elizabeth K
Brook, Mark N
Assel, Melissa
Hassan Al Battat, Mona
Thomas, Sarah
Taylor, Natalie
Chamberlain, Anthony
Pope, Jennifer
Raghallaigh, Holly Ni
Evans, D Gareth
Rothwell, Jeanette
Maehle, Lovise
Grindedal, Eli Marie
James, Paul
Mascarenhas, Lyon
McKinley, Joanne
Side, Lucy
Thomas, Tessy
van Asperen, Christi
Vasen, Hans
Kiemeney, Lambertus A
Ringelberg, Janneke
Jensen, Thomas Dyrsø
Osther, Palle J S
Helfand, Brian T
Genova, Elena
Oldenburg, Rogier A
Cybulski, Cezary
Wokolorczyk, Dominika
Ong, Kai-Ren
Huber, Camilla
Lam, Jimmy
Taylor, Louise
Salinas, Monica
Feliubadaló, Lidia
Oosterwijk, Jan C
van Zelst-Stams, Wendy
Cook, Jackie
Rosario, Derek J
Domchek, Susan
Powers, Jacquelyn
Buys, Saundra
O'Toole, Karen
Ausems, Margreet G E M
Schmutzler, Rita K
Rhiem, Kerstin
Izatt, Louise
Tripathi, Vishakha
Teixeira, Manuel R
Cardoso, Marta
Foulkes, William D
Aprikian, Armen
van Randeraad, Heleen
Davidson, Rosemarie
Longmuir, Mark
Ruijs, Mariëlle W G
Helderman van den Enden, Apollonia T J M
Adank, Muriel
Williams, Rachel
Andrews, Lesley
Murphy, Declan G
Halliday, Dorothy
Walker, Lisa
Liljegren, Annelie
Carlsson, Stefan
Azzabi, Ashraf
Jobson, Irene
Morton, Catherine
Shackleton, Kylie
Snape, Katie
Hanson, Helen
Harris, Marion
Tischkowitz, Marc
Taylor, Amy
Kirk, Judy
Susman, Rachel
Chen-Shtoyerman, Rakefet
Spigelman, Allan
Pachter, Nicholas
Ahmed, Munaza
Ramon Y Cajal, Teresa
Zgajnar, Janez
Brewer, Carole
Gadea, Neus
Brady, Angela F
van Os, Theo
Gallagher, David
Johannsson, Oskar
Donaldson, Alan
Barwell, Julian
Nicolai, Nicola
Friedman, Eitan
Obeid, Elias
Greenhalgh, Lynn
Murthy, Vedang
Copakova, Lucia
Saya, Sibel
McGrath, John
Cooke, Peter
Rønlund, Karina
Richardson, Kate
Henderson, Alex
Teo, Soo H
Arun, Banu
Kast, Karin
Dias, Alexander
Aaronson, Neil K
Ardern-Jones, Audrey
Bangma, Chris H
Castro, Elena
Dearnaley, David
Eccles, Diana M
Tricker, Karen
Eyfjord, Jorunn
Falconer, Alison
Foster, Christopher
Gronberg, Henrik
Hamdy, Freddie C
Stefansdottir, Vigdis
Khoo, Vincent
Lindeman, Geoffrey J
Lubinski, Jan
Axcrona, Karol
Mikropoulos, Christos
Mitra, Anita
Moynihan, Clare
Rennert, Gadi
Suri, Mohnish
Wilson, Penny
Dudderidge, Tim
Offman, Judith
Kote-Jarai, Zsofia
Vickers, Andrew
Lilja, Hans
Eeles, Rosalind A
Issue Date
2019-12
Metadata
Show full item recordCitation
Page EC, Bancroft EK, Brook MN, Assel M, Al Battat MH, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European urology. 2019 Dec 1;76(6):831-42.Abstract
BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65). CONCLUSIONS: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers. PATIENT SUMMARY: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadAdditional Links
https://www.sciencedirect.com/science/article/pii/S0302283819306682?via%3Dihubhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880781/
ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2019.08.019
Scopus Count
Collections
Related articles
- Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
- Authors: Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, IMPACT Collaborators., Moss S, Eeles RA
- Issue date: 2014 Sep
- Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
- Authors: Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L, IMPACT Study Collaborators., Easton DF, Eeles RA
- Issue date: 2011 Jan
- Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
- Authors: Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K, IMPACT study collaborators., Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA
- Issue date: 2018 Jan
- Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
- Authors: Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W
- Issue date: 2014 Oct
- Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
- Authors: Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, Rosenbaum E, Sela S, Ozalvo R, Shavit-Grievink L, Keder D, Baniel J, Margel D
- Issue date: 2020 Nov